We scan new podcasts and send you the top 5 insights daily.
Roloff says getting the privacy technology in place is usually the easy part. The harder work is communicating with regulators, standards bodies and policy authorities about changing workflows and liability. He personally meets with Capitol Hill, White House and NIST/OSTP officials to move that conversation forward.
Kurt Roloff says large pharma often treats compliance as a cost center, but secure collaboration can turn existing data into a profit enabler. It lets divisions and companies reuse data across geographies, cutting IRB and administrative overhead so rare pediatric cancer research becomes more cost efficient.
To overcome data silos in a regulated environment, CIBC prioritized building internal trust. They proactively brought legal, compliance, and privacy teams together, clearly defining the use case and value of unified data, which was critical for gaining enterprise-wide approval.
A major hurdle for Palantir’s engineers isn't just technical; it's navigating internal client politics. Middle managers often resist sharing data due to inertia or fear of becoming obsolete, making political maneuvering a critical and overlooked part of Palantir's implementation process and value.
Roloff notes data officers hesitate because 'no one ever gets fired for saying no,' making them fear exposure. Strong encryption guarantees and GDPR court acceptance, he says, reduce the perceived liability of sharing rather than just the technical risk. That reframes data repositories as potential value sources instead of cost centers.
While the computational problem of finding a proof is intractable, the real-world bottleneck is the human process of defining the specification. Getting stakeholders to agree on what a property like "all data at rest is encrypted" truly means requires intense negotiation and is by far the most difficult part.
In multinational military operations, the primary obstacle to creating a common operating picture isn't technical interoperability; it's the regulations and bureaucracy tied to data ownership. Each nation's policies create significant hurdles that technology alone cannot solve.
The development of powerful foundation models to optimize bioprocessing is hampered less by technical challenges and more by the industry's reluctance to share data. The critical challenge is overcoming the cultural and legal hurdles within companies to create the large, diverse datasets necessary for transformative AI.
Executives from both fintech and crypto-native firms agree that the engineering work is the most straightforward part of launching a crypto product. The primary obstacles lie in managing regulators, navigating state-by-state legal frameworks, and getting stakeholder buy-in, making legal and policy teams more critical than dev teams for go-to-market.
Digital trust with partners requires embedding privacy considerations into their entire lifecycle, from onboarding to system access. This proactive approach builds confidence and prevents data breaches within the extended enterprise, rather than treating privacy as a reactive compliance task.
Roloff agrees that AI in medicine is constrained less by models or compute than by access to sensitive data. He says privacy technology is ahead of community acceptance; secure inference through commercial trusted execution environments is emerging, but training large foundational models on patient data remains the 'golden apple' still being pursued.